# A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

> **NCT00165633** · PHASE2,PHASE3 · TERMINATED · sponsor: **Eisai Limited** · enrollment: 540 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Menatetrenone
- **DRUG:** Menatetrenone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00165633
- **Lead sponsor:** Eisai Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2008-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165633, "A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00165633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*